Zobrazeno 1 - 10 of 19 pro vyhledávání: '"Kenneth Joel Bloom"'
1
A preliminary review of adoption of new HCPCS codes for NGS in CMS claims
Autor: Dave Smart, Wendy Moore, Susanne Munksted Fosvig, Kenneth Joel Bloom
Publikováno v: Journal of Clinical Oncology. 40:e13522-e13522
e13522 Background: Adequate reimbursement is considered a prerequisite for adoption of new diagnostic technologies that facilitate patient access to better treatments. Detailed longitudinal investigation of the adoption of new HCPCS codes and the fac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::458d8d12fb99b6d2a07230aea208fb14
https://doi.org/10.1200/jco.2022.40.16_suppl.e13522
Zobrazit plný text záznamu
2
AI-enabled identification prediction of homologous recombination deficiency (HRD) from histopathology images
Autor: Gowhar Shafi, Shivamurthy P.M., Anand Ulle, Krithika Srinivasan, Aravindan Vasudevan, Vikas Jadhav, Dr Sujit Joshi, Nirmal Vivek Raut, Jayant Khandare, Mohan Uttarwar, Kenneth Joel Bloom
Publikováno v: Journal of Clinical Oncology. 40:3019-3019
3019 Background: Homologous recombination deficient (HRD) tumors are highly responsive to platinum-based chemotherapy and poly (ADP-ribose) polymerase inhibitor (PARPi) therapy. Pathogenic BRCA-1 and BRCA-2 (BRCA1/2) alterations are key members of th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a7c6bed770a93662fb690d6b8fc7cfa
https://doi.org/10.1200/jco.2022.40.16_suppl.3019
Zobrazit plný text záznamu
3
Effect of COVID-19 Pandemic Control Measures on Diagnoses of Hematologic Cancer Among CMS Population in 2020
Autor: Kenneth Joel Bloom, Dave Smart, Peter Riccelli, Raymond Henderson, Anthony M. Magliocco, Karina Hjort, Bob Holt, Karen Keating, Curtis A. Hanson, Wendy Moore
Publikováno v: Blood
Introduction Measures taken to mitigate infection spread during the 2020 COVID-19 pandemic are considered to have caused significant unintended consequences on other diseases. Large decreases in the numbers of symptomatic and asymptomatic people pres
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2661afed3654de5e69e623b86c8ad610
http://europepmc.org/articles/PMC8701593
Zobrazit plný text záznamu
4
Drugging the undruggable: A market readiness analysis for KRAS-G12C
Autor: Isabel Stacey, Jordan Clark, Kenneth Joel Bloom, Nital Patel, Enya Scanlon, Fotios Loupakis, Derry Mae Keeling, Wendy L. Allen
Publikováno v: Journal of Clinical Oncology. 38:e15667-e15667
e15667 Background: KRAS G12C is a distinctively aggressive, poor survival, tumor genotype conferring resistance to anti-EGFR therapies in lung, colorectal (CRC) and pancreatic cancers. Prospective therapies targeting G12C have demonstrated promising
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1da7f7f6b745d13c65b7ce10fe2a1a4
https://doi.org/10.1200/jco.2020.38.15_suppl.e15667
Zobrazit plný text záznamu
5
Stability of rare TP53 co-mutations in AML patients
Autor: Jordan Clark, Wendy L. Allen, Kenneth Joel Bloom, Adam Idica, Enya Scanlon, Dave Smart
Publikováno v: Journal of Clinical Oncology. 38:7528-7528
7528 Background: Acute Myeloid Leukemia (AML) is a devastating disease with poor overall survival. Access to precision medicines, is revolutionizing AML care and is driving an increase in Next Generation Sequencing (NGS) utilization to determine the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7771ee7851d122294929d1b769aff745
https://doi.org/10.1200/jco.2020.38.15_suppl.7528
Zobrazit plný text záznamu
6
Use of real-world clinical lab data to reveal Asian NTRK fusion test availability patterns
Autor: Jordan Clark, Marieke Hoefsmit, Markus Eckstein, Kenneth Joel Bloom, Susanne Munksted Fosvig
Publikováno v: Journal of Clinical Oncology. 38:e15574-e15574
e15574 Background: The development and launch of first-generation tropomyosin receptor kinase (TRK) inhibitors, such as larotrectinib and entrectinib, has brought targeted treatment options to neurotrophic tropomyosin-related kinase (NTRK) fusion–p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::216a4e6c44aaa3777647708a7ce39c80
https://doi.org/10.1200/jco.2020.38.15_suppl.e15574
Zobrazit plný text záznamu
7
Hrd in ovarian cancer: Defined today, evolving for the future
Autor: Peter Riccelli, Markus Eckstein, Kenneth Joel Bloom, Jordan Clark, Frank Policht, Derry Mae Keeling
Publikováno v: Journal of Clinical Oncology. 38:e18052-e18052
e18052 Background: Homologous Recombination Repair (HRR) gene mutations result in Homologous Recombination Deficiency (HRD) associated with increased risk of high grade serous ovarian (HGOC) cancer and subsequent response to PARP inhibitors (PARPi).
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::09b4d91db50d002171a9858c21d6d38c
https://doi.org/10.1200/jco.2020.38.15_suppl.e18052
Zobrazit plný text záznamu
8
Economic burden of not testing for FLT3 to treat acute myeloid leukemia
Autor: Mark Lawler, Dave Smart, Kenneth Joel Bloom, Jordan Clark, Raymond Henderson, Derek Hosty, Declan French
Publikováno v: Journal of Clinical Oncology. 38:e13652-e13652
e13652 Background: Acute myeloid leukemia (AML) is a hematologic neoplasm with poor 5-year survival (33%; US 2016), a median survival of only 4 months for relapsed/refractory cases, and in 2016, a US incidence of 19,950 cases and 10,340 deaths. With
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::01f4efc35e4e3f70d8a4aed4d8d21be5
https://doi.org/10.1200/jco.2020.38.15_suppl.e13652
Zobrazit plný text záznamu
9
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer
Autor: Fernando Lopez-Rios, Frédérique Penault-Llorca, Andrew Wotherspoon, Keith Kerr, John W. Longshore, Julien Adam, Giuseppe Viale, Manfred Dietel, Noriko Motoi, John R Gosney, Ming-Sound Tsao, Birgit Guldhammer Skov, Kenneth Joel Bloom, Reinhard Büttner
Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2017, 35 (34), pp.3867-3876. ⟨10.1200/JCO.2017.74.7642⟩
Purpose Three programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for treatment of non–small-cell lung cancer (NSCLC). Treatment with pembrolizumab in NSCLC requires PD-L1 immunohistochemistry (IHC) testing. Nivol
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::581a5be10ff02c7ebe6ca78db20239c6
https://hal.archives-ouvertes.fr/hal-01675259
Zobrazit plný text záznamu
10
The blood DNA virome in 8,000 humans
Autor: Yaron Turpaz, William H. Biggs, Eric Delwart, Kenneth Joel Bloom, Karen E. Nelson, Amalio Telenti, Chao Xie, Ahmed A. Moustafa, Ewen F. Kirkness, Emily H. M. Wong, J. Craig Venter
Publikováno v: PLoS Pathogens
PLoS Pathogens, Vol 13, Iss 3, p e1006292 (2017)
The characterization of the blood virome is important for the safety of blood-derived transfusion products, and for the identification of emerging pathogens. We explored non-human sequence data from whole-genome sequencing of blood from 8,240 individ
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::819b74b67ddf11c833ae0a6a6d1746ef
http://europepmc.org/articles/PMC5378407
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje